
|Videos|November 12, 2013
The Background and Future of Quizartinib for AML
Author(s)Mark J. Levis, MD, PhD
Mark J. Levis, MD, PhD, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.
Advertisement
Clinical Pearls
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.
- Quizartinib could play a crucial role in the treatment of FLT3-ITD acute myeloid leukemia
- Quizartinib has produced many clinically meaningful responses
- The phase IIb study will analyze 30 mg and 60 mg doses
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















